Loading...
•
Dec 31, 2022
Viridian Therapeutics Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
Viridian Therapeutics reported its Q4 2022 financial results, with a net loss of $45.8 million. The company's cash, cash equivalents, and short-term investments totaled $424.6 million as of December 31, 2022, and they believe it will be sufficient to fund operations into the second half of 2025.
Reported positive data from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED).
First patient enrolled in ‘THRIVE’ Phase 3 trial in patients with active TED, with results expected in mid-2024.
Initial results from the proof-of-concept study of VRDN-001 in patients with chronic TED are expected in the second quarter of 2023.
Selection of lead subcutaneous program in TED planned for year-end 2023.